Skip to main content
Skip to main content
BCPC logo

Balchem Corporation (BCPC) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$166.67 -$1.67 (-0.99%) |Exceptional · 83
Balchem Corporation (BCPC) bottom line: Bullish Lean — our Council read (63/100) and AI Score (83/100) broadly agree. Strongest signal: Financial Safety strong · Biggest watch-out: Seth Klarman bearish.Educational signal, not a buy or sell recommendation. Compare sector peers → · Read the method →
MCap: $5.36B| P/E Ratio: 32.55| Vol: 127.8K| Target: $215.00 (+29.0%) (Aug 25, 2026) (estimate, not advice)| 52-wk range: $139.17 – $183.90

P/E 32.55 means the share price is 32.55 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $5.36B is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Balchem Corporation (BCPC) trades at $166.67 with MoonshotScore 83/100 (Grade A+). Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across various sectors, including nutrition, food, pharmaceuticals, and animal health. Market cap: $5.36B, Sector: Basic materials.

Price as of Sep 10, 2026 · Last analyzed: May 10, 2026
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across various sectors, including nutrition, food, pharmaceuticals, and animal health. The company operates globally, providing solutions from microencapsulation to chelated minerals.

BCPC stock analysis for 2026: Analysts have set a consensus price target of $215.00 for Balchem Corporation, suggesting 29.0% upside from the current price of $166.67. The AI MoonshotScore is 83/100, in the Exceptional band (80-100) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the BCPC film Every key number, told as a short cinematic story — just press play. ~2 min

These figures come from statements filed 12 months ago — the most recent this company has published.

Council Score · Weighted Average of 3 Disciplines
Bullish Lean 63/100 · B+

BCPC: 2/3 scored disciplines lean bullish. Dominant signal: Financial Safety strong.

How is this calculated? →
MoonshotScore · Five-pillar engine · 83/100
Business Quality
Moderate Is this a genuinely good business?
Financial Safety
Strong Could this blow up on me?
Valuation
Weak Am I paying a fair price?
Growth Durability
Strong Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?

Strongest side: Financial Safety (10/10, Strong). Weakest side: Valuation (3/10, Weak).

Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated)Ken Griffin
Neutral read
Englander-style lens (simulated)Izzy Englander
Unfavorable read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Neutral read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Moderate
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Balchem Corporation (BCPC) Materials & Commodity Exposure

CEOTheodore Lee Harris
Employees1,379
HeadquartersMontvale, NY, US
IPO Year1986

Balchem Corporation, a specialty chemicals company, focuses on developing and marketing performance ingredients for human and animal nutrition, along with specialty products for healthcare and industrial applications. With a diverse portfolio and global reach, Balchem serves a wide range of markets through its three key segments.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for BCPC?

AI-written as of May 10, 2026 — figures and tone reflect the data available then, not today's score.

With a P/E ratio of 32.55 and a profit margin of 15.0%, the company demonstrates solid profitability. Key growth catalysts include expanding its microencapsulation technology and chelated minerals offerings. The company's ability to innovate and adapt to changing market demands, coupled with its established distribution network, positions it for sustained growth. However, potential risks include fluctuations in raw material costs and increased competition in the specialty chemicals market. Investors should monitor the company's ability to maintain its gross margin of 36.3% and dividend yield of 0.60%.

Based on FMP financials and quantitative analysis

BCPC Key Highlights

AI-written as of May 10, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $5.36B indicates a strong market presence.

  • P/E ratio of 32.55 reflects investor expectations of future earnings growth.
  • Profit margin of 15.0% demonstrates efficient operations and pricing strategy.
  • Gross margin of 36.3% highlights the company's ability to manage production costs effectively.
  • Dividend yield of 0.60% provides a modest income stream for investors.

Who Are BCPC's Competitors?

BCPC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
ESI Element Solutions Inc. $34.33 +0.45% $8.36B 565-pillar
SSL Sasol Limited $14.54 -0.75% $9.27B 975-pillar
AXTA Axalta Coating Systems Ltd. $34.02 -1.22% $7.28B 675-pillar
EGO Eldorado Gold Corporation $42.79 -4.02% $11.2B 855-pillar
SSRM SSR Mining Inc. $36.21 -3.70% $7.51B 995-pillar
SXT Sensient Technologies Corporation $131.06 -1.51% $5.58B 685-pillar
FUPEF Fuchs Petrolub SE $37.00 0.00% $4.85B 499-signal
CBT Cabot Corporation $78.84 +0.06% $4.07B 675-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BCPC's Key Strengths?

Diversified product portfolio

  • Strong market position in specialty ingredients
  • Proprietary technologies
  • Global distribution network

What Are BCPC's Weaknesses?

Dependence on raw material prices

  • Exposure to regulatory changes
  • Limited brand recognition compared to larger competitors
  • Potential for supply chain disruptions

What Could Drive BCPC Stock Higher?

Continued expansion of microencapsulation technology into new applications.

  • Increasing demand for chelated minerals in animal nutrition and high-value crops.
  • Potential acquisitions of complementary businesses to expand product offerings.
  • Growth in the medical device sterilization market driving demand for ethylene oxide.
  • Innovation in human nutrition and health leading to new product development.

What Are the Key Risks for BCPC?

Rich valuation — a P/E of 32.55 runs well above the Basic Materials sector’s ~21.40x, leaving little room for a miss.

  • Fluctuations in raw material costs impacting profit margins.
  • Increased competition from larger chemical companies.
  • Economic downturns affecting demand for specialty ingredients.
  • Regulatory changes impacting the use of ethylene oxide in medical device sterilization.
  • Supply chain disruptions affecting the availability of key ingredients.

What Are the Growth Opportunities for BCPC?

  • Expansion of Microencapsulation Technology: Balchem can further expand its microencapsulation technology across various applications, including pharmaceuticals, food, and animal nutrition. The global microencapsulation market is projected to reach $12.5 billion by 2028, offering significant growth potential. By investing in R&D and strategic partnerships, Balchem can enhance its market share and develop innovative solutions for targeted drug delivery and nutrient release.
  • Increased Adoption of Chelated Minerals: The demand for chelated minerals in animal nutrition and high-value crops is increasing due to their enhanced bioavailability and absorption. Balchem can capitalize on this trend by expanding its chelated mineral product line and targeting new markets. The global chelated minerals market is expected to grow at a CAGR of 6.5% from 2021 to 2028, driven by the need for improved animal health and crop yields.
  • Growth in Medical Device Sterilization: The Specialty Products segment, which offers ethylene oxide for medical device sterilization, presents a significant growth opportunity. With increasing healthcare regulations and the growing demand for sterilized medical devices, Balchem can expand its market share by providing reliable and efficient sterilization solutions. The global medical device sterilization market is projected to reach $10.5 billion by 2027.
  • Strategic Acquisitions and Partnerships: Balchem can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies and market access, Balchem can accelerate its growth and strengthen its competitive position. This includes exploring opportunities in emerging markets and expanding its presence in key regions.
  • Innovation in Human Nutrition & Health: Balchem can focus on developing innovative ingredients and solutions for the human nutrition and health market, including functional foods, dietary supplements, and personalized nutrition products. By investing in R&D and collaborating with food and beverage companies, Balchem can create value-added products that meet the evolving needs of consumers.

What Are BCPC's Competitive Advantages?

  • Specialized product portfolio with niche applications.
  • Strong relationships with key customers.
  • Proprietary technologies, including microencapsulation and chelation.
  • Established distribution network and global reach.

What Does BCPC Do?

Balchem Corporation, founded in 1967 and headquartered in New Hampton, New York, develops, manufactures, and markets specialty performance ingredients and products. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment provides ingredients for the food and beverage industry, including spray dried and emulsified powders, liquid flavor delivery systems, and microencapsulation solutions. This segment also offers human-grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment focuses on enhancing animal health and productivity by providing microencapsulated products and chelation technology for nutrient absorption. The Specialty Products segment offers ethylene oxide for healthcare sterilization and propylene oxide as a fumigant for controlling insects and microbiological spoilage in various food products. Balchem sells its products through a direct sales force, independent distributors, and sales agents, serving the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets globally.

What Products and Services Does BCPC Offer?

  • Develops and manufactures specialty performance ingredients.
  • Offers solutions for human nutrition and health.
  • Provides products for animal nutrition and health.
  • Supplies ethylene oxide for medical device sterilization.
  • Markets propylene oxide as a fumigant.
  • Offers chelated minerals for high-value crops.
  • Provides microencapsulation solutions for various applications.

How Does BCPC Make Money?

  • Develops and manufactures specialty ingredients and products.
  • Sells products through a direct sales force, independent distributors, and sales agents.
  • Generates revenue from three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
  • Focuses on innovation and customization to meet specific customer needs.

What Industry Does BCPC Operate In?

Balchem Corporation operates within the specialty chemicals industry, which is characterized by innovation, customization, and a focus on specific applications. The market is driven by increasing demand for performance ingredients in the food, nutrition, and healthcare sectors. Balchem competes with companies like Element Solutions Inc. (ESI), Sasol Limited (SSL), and Axalta Coating Systems Ltd. (AXTA). The industry is experiencing growth due to rising health awareness and the need for advanced sterilization solutions. Balchem's diversified product portfolio and global reach position it well to capitalize on these trends.

Who Are BCPC's Key Customers?

  • Food and beverage companies
  • Pharmaceutical companies
  • Animal feed manufacturers
  • Healthcare providers
  • Agricultural producers
Model self-rating on this text: 73% (not a measure of the evidence) Updated: May 10, 2026

Research confidence

High 75/100

Broad, current evidence sits behind this analysis.

  • Scored on 100% of our measures
  • Price is current
  • No filing on record
  • Covered by analysts

Why 83?

Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.

What is helping

  • +0.60 Bankruptcy-risk score (Financial Strength)
  • +0.31 Net margin (Business Quality)
  • +0.27 Financial-health checklist (Financial Strength)

What is holding it back

  • -0.14 Enterprise value vs EBITDA (Valuation)
  • -0.12 Enterprise value vs sales (Valuation)
  • -0.10 Price to book (Valuation)

Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 87
2026-08-26 88
2026-08-29 90
2026-09-01 84
2026-09-04 82
2026-09-07 83
2026-09-10 83

What changed?

The grade moved from 87 to 83 (-4).

What moved it up or down:

  • -9 Valuation
  • -8 Momentum
  • -1 Business Quality

Held back by:

  • +1 Financial Safety

Over the same 18 days the stock moved -8.1%.

FY2026 est

Forward Outlook

Wall Street analysts project Balchem Corporation revenue of about $1.13B for fiscal 2026, with EPS near $5.40. The estimate reflects 3 contributing analysts.

4/8 beats

Earnings Track Record

Balchem Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses.

F-Score 9/9

Financial Health

Balchem Corporation's Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 10.60 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 12%

Key Financial Metrics

Return on equity for Balchem Corporation stands at 12.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.3%, showing how much profit it generates from its asset base. BCPC trades at a trailing price-to-earnings ratio of 32.55, above the Basic Materials sector average of ~21.40x. Its free cash flow yield is 3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.0%, the inverse of the P/E and a quick read on earnings relative to price.

Balchem Corporation (BCPC) Valuation Context

Valued at $5.36B, BCPC is classified as a mid-cap stock. Analyst price targets span from $215.00 to $215.00, with a consensus of $215.00. At the current price of $166.67, that implies approximately 29% upside potential. Relative to its peer group, BCPC's quantitative score of 83/100 is roughly in line with the peer average of 74/100.

BCPC Revenue & Earnings Trend

In Jun 2026, BCPC generated $284.0M in top-line revenue, marking a sequential increase of 4.9%. The company recorded net income of $44.6M, with diluted EPS of $1.38. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Basic Materials company. Across the four most recent quarters, BCPC averaged $1.27 in diluted EPS.

Company Profile

Balchem Corporation operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in Montvale, US. The company is led by CEO Theodore L. Harris. BCPC has traded publicly since 1986.

BCPC Financials

Fundamental Snapshot

Revenue Growth (FY)
+8.8%
Net Income Growth (FY)
+20.5%
EPS Growth (FY)
+20.9%
Free Cash Flow Growth (FY)
+18.3%
P/E (TTM)
32.55
Return on Equity (TTM)
+12.4%
Current Ratio
2.5
EV/EBITDA (TTM)
19.5

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Diversified product portfolio
  • Strong market position in specialty ingredients
  • Proprietary technologies
  • Global distribution network

Bear Case

  • Dependence on raw material prices
  • Exposure to regulatory changes
  • Limited brand recognition compared to larger competitors
  • Potential for supply chain disruptions

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Jun 2026 $284M $45M $1.38
Mar 2026 $271M $40M $1.25
Dec 2025 $264M $39M $1.21
Sep 2025 $268M $40M $1.23

Based on FMP financials and quantitative analysis

BCPC Latest News

BCPC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BCPC.

Price Targets

Low
$215.00
Consensus
$215.00
High
$215.00

Median: $215.00 (+29.0% from current price)

Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice

BCPC MoonshotScore

83/100

What does this score mean?

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. BCPC scores 83/100 (Grade A+): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Leadership: Theodore Lee Harris

CEO

Theodore Lee Harris serves as the CEO of Balchem Corporation. His background includes extensive experience in the specialty chemicals and ingredients industry. He has held various leadership positions, demonstrating expertise in strategic planning, operational excellence, and business development. His career reflects a strong focus on driving growth and innovation within the organization.

Track Record: Under Theodore Lee Harris's leadership, Balchem Corporation has focused on expanding its product portfolio and strengthening its market position. Key achievements include strategic acquisitions and partnerships, as well as investments in research and development. The company has also focused on improving operational efficiency and enhancing customer relationships, contributing to sustained growth and profitability.

Common Questions About BCPC (Basic Materials)

What does the AI Score mean for BCPC?

BCPC holds an AI Score of 83/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is BCPC a good stock?

Stock Expert AI does not rate BCPC buy, sell or hold. Balchem Corporation carries a MoonshotScore of 83/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What do analysts say about BCPC stock?

Analyst coverage of Balchem Corporation (BCPC) typically focuses on its growth prospects, profitability, and competitive positioning within the specialty chemicals industry. Key valuation metrics include the P/E ratio, profit margin, and gross margin.

What are the key factors to evaluate for BCPC?

Balchem Corporation (BCPC) holds a MoonshotScore of 83/100 (high). P/E: 32.55x vs the S&P 500's ~20-25x. Analysts target $215.00 (+29%). Not financial advice.

How frequently does BCPC data refresh on this page?

BCPC's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven BCPC's recent stock price performance?

Balchem Corporation (BCPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BCPC overvalued or undervalued right now?

Balchem Corporation (BCPC) trades at 32.55x earnings. Analysts target $215.00 (+29%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of BCPC?

Yes, most major brokerages offer fractional shares of Balchem Corporation (BCPC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track BCPC's earnings and financial reports?

Balchem Corporation (BCPC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BCPC earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated MoonshotScore as of
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover